Histidine Decarboxylase Expression As a New Sensitive and Specific Marker for Small Cell Lung Carcinoma
Overview
Affiliations
Histidine decarboxylase is one of the enzymes of the amine precursor uptake and decarboxylation system and is known to be distributed in mast cells and enterochromaffin-like cells. With the hypothesis that histidine decarboxylase expression is a marker for neuroendocrine differentiation, we studied the immunoreactivity of histidine decarboxylase in neuroendocrine cells and tumors of the thyroid gland, adrenal medulla, lung, and gastrointestinal tract. Formalin-fixed paraffin sections were subjected to immunohistochemistry using anti-histidine decarboxylase antibody, and the sensitivity and specificity were compared with those of conventional neuroendocrine markers (CD56, chromogranin A, synaptophysin, and neuron-specific enolase). Enterochromaffin or enterochromaffin-like cells, adrenal chromaffin cells, and thyroid C-cells were positive for histidine decarboxylase, and related tumors (carcinoid tumor, pheochromocytoma, medullary carcinoma) showed a high percentage of positive staining. Furthermore, we used the antibody to distinguish small cell lung carcinoma from non-neuroendocrine lung carcinoma and also to detect neuroendocrine differentiation in large-cell neuroendocrine carcinoma and gastrointestinal small-cell carcinoma. The anti-histidine decarboxylase antibody stained most small cell lung carcinoma (18 of 23, sensitivity 0.78), and was rarely reactive with non-neuroendocrine lung tumors (2 of 44; specificity, 0.95). These values were close to those obtained from CD56 staining (sensitivity/specificity, 0.87/0.98). Histidine decarboxylase was also positive for 6 of 12 large cell neuroendocrine carcinomas and 4 of 7 gastrointestinal small cell carcinomas. In conclusion, we demonstrated that histidine decarboxylase is useful to distinguish between small cell lung carcinoma and non-neuroendocrine carcinoma and to demonstrate neuroendocrine differentiation.
SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
Yu L, Dong Y, Xue J, Xu S, Wang G, Kuang D Diagn Pathol. 2022; 17(1):2.
PMID: 34996493 PMC: 8742448. DOI: 10.1186/s13000-021-01186-0.
Waldum H, Oberg K, Sordal O, Sandvik A, Gustafsson B, Mjones P Therap Adv Gastroenterol. 2018; 11:1756284818775054.
PMID: 29872453 PMC: 5974566. DOI: 10.1177/1756284818775054.
Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics.
Klupczynska A, Derezinski P, Garrett T, Rubio V, Dyszkiewicz W, Kasprzyk M J Cancer Res Clin Oncol. 2017; 143(4):649-659.
PMID: 28168355 PMC: 5352735. DOI: 10.1007/s00432-017-2347-0.
Truta-Feles K, Lagadari M, Lehmann K, Berod L, Cubillos S, Piehler S Br J Pharmacol. 2010; 161(6):1291-300.
PMID: 20977468 PMC: 3000654. DOI: 10.1111/j.1476-5381.2010.00639.x.
Wang K, Tanimoto A, Yamada S, Guo X, Ding Y, Watanabe T Am J Pathol. 2010; 177(2):713-23.
PMID: 20566747 PMC: 2913336. DOI: 10.2353/ajpath.2010.091198.